Press Releases

– Intellia’s Right to Use Proprietary Lipid Nanoparticle Technology Extended to All Settings – Intellia Will Receive a One-time $10 Million Payment CAMBRIDGE, Mass. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing

CAMBRIDGE, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will participate in the following upcoming healthcare conferences in

Enhanced in vivo CRISPR/Cas9 cargo components have led to substantially increased liver editing and protein reduction in non-human primates that could materially improve its transthyretin amyloidosis and other in vivo product profiles Integration of enhanced components into its lead transthyretin

CAMBRIDGE, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present third quarter 2018 results and corporate developments in

CAMBRIDGE, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has named Glenn Goddard its executive vice president and chief

Intellia scientists present first robust demonstration of CRISPR-mediated insertion of  transgenes in the liver Non-human primate data show high correlation achieved between  liver edit and reduction of TTR protein High rate and specificity of acute myeloid leukemia cell killing observed  with

CAMBRIDGE, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate in the following upcoming healthcare conferences in October: Monday,

The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells   University of California/University of Vienna /Dr. Charpentier have patent applications covering the use of CRISPR/Cas9 genome editing technology

CAMBRIDGE, Mass. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate in the following upcoming healthcare conferences in September: Tuesday,

  Robust, dose-responsive liver editing and reduction of TTR protein shown  in humanized mouse model Therapeutically relevant reduction of serum TTR protein correlating with liver editing achieved in non-human primates after a single dose CAMBRIDGE, Mass. , Aug.